Accelerating recruitment for an early-phase oncology study
Clarenta supported a Phase I oncology study requiring accelerated recruitment, intensive pharmacokinetic sampling and coordination with patients’ chemotherapy schedules.
Our integrated recruitment and site-support model enabled a single Bulgarian research centre to enrol 36 patients within approximately two months.
Exceeding recruitment goals in Phase II asthma study
Clarenta supported patient recruitment and clinical monitoring across three Bulgarian sites participating in a Phase II Proof-of-Concept study in adults with moderate-to-severe asthma.
Our coordinated site-support model enabled the three sites to enroll 48 participants, with the leading site nearly doubling its contractual recruitment target.
Clinical operations gap analysis for an early-phase glioblastoma trial
Clarenta conducted an independent clinical operations gap analysis for an early-phase glioblastoma trial experiencing recruitment and operational challenges.
Our assessment identified weaknesses in the recruitment strategy, vendor responsibilities, communication pathways and project management, enabling the Sponsor to prioritize corrective actions.
Providing embedded clinical operations leadership for a first-in-human oncology trial
Clarenta operated as an extension of a European biotechnology company’s clinical operations team for a first-in-human Phase I/IIa oncology trial.
Our embedded model covered European trial execution, regulatory submissions, vendor management and oversight of the US CRO while supporting demanding operational timelines.
Phase I PK & clinical pharmacology in atopic dermatitis
Clarenta supported a dose-escalation study evaluating an investigational topical therapy in adults with mild-to-moderate atopic dermatitis.
Our targeted recruitment strategy and integrated dermatology and clinical pharmacology expertise enabled the complete planned study population to be recruited within approximately four months.